title: Ciclopirox nail lacquer 8% for the treatment of onychomycosis: a Canadian perspective.
abstract: Onychomycosis is prevalent in the Canadian population, and risk factors, such as old age and diabetes, are increasing. This condition has traditionally been treated using oral antifungal agents with varying degrees of success. Recently, ciclopirox nail lacquer 8% solution became the first topical agent approved in Canada for onychomycosis. Ciclopirox nail lacquer may be safe and effective for the treatment of onychomycosis, and certain candidates may benefit from therapy. Ciclopirox may be implicated for prophylactic use in order to prevent recurrent infection and may be used in combination with oral agents.
authors.affiliation: Division of Dermatology, Department of Medicine, Sunnybrook and Women's College Health Sciences Centre (Sunnybrook site) and the University of Toronto, Toronto, Canada.
authors.forename: A K
authors.initials: AK
authors.lastname: Gupta
authors.forename: J R
authors.initials: JR
authors.lastname: Schouten
authors.forename: L E
authors.initials: LE
authors.lastname: Lynch
mesh_terms: D000935:Antifungal Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002170:Canada; D000077768:Ciclopirox; D006801:Humans; D014009:Onychomycosis / Q000188:drug therapy*; D011728:Pyridones / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D011728:Pyridones; D000077768:Ciclopirox